不同剂量辛伐他汀对血脂异常患者糖代谢的影响

Impact of different doses of simvastatin on glucose metabolism in the treatment of patients with dyslipidemia

目的探讨不同剂量辛伐他汀治疗对血脂异常患者糖代谢的影响。方法选择2014年1~8月来我院接受治疗的血脂异常患者120例,按照数表法随机平均分为A、B、C三组,每组各40例,其中A组患者每天使用辛伐他汀10 mg,B组患者为20 mg,C组患者为40 mg,治疗3个月后比较三组患者治疗后的血脂水平变化和糖代谢情况。结果 1A、B、C三组患者治疗后的低密度脂蛋白胆固醇（LDL-C）分别为（2.83±0.52）mmol/L、（2.72±0.49）mmol/L和（1.71±0.32）mmol/L,差异有统计学意义（P〈0.05）;高密度脂蛋白胆固醇（HDL-C）分别为（1.26±0.43）mmol/L、（1.32±0.47）mmol/L、（1.36±0.51）mmol/L,差异有统计学意义（P〈0.05）;总胆固醇（TC）分别为（4.71±0.40）mmol/L、（4.32±0.31）mmol/L、（3.65±0.35）mmol/L,差异有统计学意义（P〈0.05）;甘油三酯（TG）分别为（1.89±0.63）mmol/L、（1.85±0.61）mmol/L、（1.67±0.29）mmol/L,差异有统计学意义（P〈0.05）;2治疗后三组患者的糖化血红蛋白与餐前及餐后血糖均轻微升高,胰岛素水平无明显变化,经比较差异均无统计学意义（P〉0.05）。结论将辛伐他汀应用于血脂异常患者,剂量与疗效密切相关,较大剂量辛伐他汀具有高效性,但不同剂量辛伐他汀对糖代谢无明显影响。

Objective To investigate the impact of different doses of simvastatin on glucose metabolism in the treatment of dyslipidemia. Methods One hundred and twenty patients of dyslipidemia were selected in our hospi-tal from January 2012 to August 2014, which were divided into three groups （group A, B, C, with 40 patients in each group） according to random number table. Group A was treated with simvastatin 10 mg daily, group B was treated with 20 mg daily, and group C was treated with 40 mg daily. Changes of lipid levels and blood glucose after treatment （3 months） of the three groups were compared. Results ① The levels of low-density lipoprotein cholesterol （LDL-C） were （2.83＆#177;0.52） mmol/L in group A, （2.72＆#177;0.49） mmol/L in group B, （1.71＆#177;0.32） mmol/L in group C, with statistically significant differences between the three groups （t=6.32, P〈0.05）. The levels of high-density lipoprotein＆amp;nbsp;cholesterol （HDL-C） were （1.26 ＆#177; 0.43） mmol/L in group A, （1.32 ＆#177; 0.47） mmol/L in group B, （1.36 ＆#177; 0.51） mmol/L in group C, with statistically significant differences between the three groups （t=5.78, P〈0.05）. Total cholesterol （TC） were （4.71±0.40） mmol/L, （4.32±0.31） mmo/L, （3.65±0.35） mmol/L, and triglyceride （TG） were （1.89±0.63） mmol/L, （1.85 ±0.61） mmol/L, （1.67±0.29） mmol/L, respectively, with statistically significant differences between the three groups （t=4.33, P〈0.05）. ② The glycosylated hemoglobin （HbAlc）, blood sugar levels before and after meal in the three groups were all slightly elevated, and insulin levels showed no significant changes, with no statistically signifi-cant differences between the three groups （P＆gt;0.05）. Conclusion The dose of simvastatin in treatment of patients with dyslipidemia is closely related to efficacy. Large doses of simvastatin tend to result in higher security and efficien-cy, but different doses of simvastatin has no significant effect on glucose metabolism.